AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
200.80
+2.12 (+1.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close198.68
Open200.23
Bid0.00 x 800
Ask0.00 x 900
Day's Range199.98 - 203.87
52 Week Range166.30 - 211.90
Volume2,477,386
Avg. Volume2,986,410
Market Cap120.42B
Beta (3Y Monthly)0.79
PE Ratio (TTM)15.94
EPS (TTM)12.60
Earnings DateOct 29, 2019
Forward Dividend & Yield5.80 (2.92%)
Ex-Dividend Date2019-08-14
1y Target Est216.05
Trade prices are not sourced from all markets
  • These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls
    MarketWatch

    These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls

    Sen. Elizabeth Warren’s health-care reform crusade is rattling biotech investors — but that’s not the industry’s only problem, writes Michael Brush.

  • Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off
    Investor's Business Daily

    Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off

    Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.

  • Top Research Reports for Toyota, Amgen & TJX
    Zacks

    Top Research Reports for Toyota, Amgen & TJX

    Top Research Reports for Toyota, Amgen & TJX

  • Alexion (ALXN) Collaborates With Stealth BioTherapeutics
    Zacks

    Alexion (ALXN) Collaborates With Stealth BioTherapeutics

    Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

  • 3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
    Zacks

    3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

    Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

  • Should You Be Worried About Insider Transactions At Amgen Inc. (NASDAQ:AMGN)?
    Simply Wall St.

    Should You Be Worried About Insider Transactions At Amgen Inc. (NASDAQ:AMGN)?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • Amgen (AMGN) Gains But Lags Market: What You Should Know
    Zacks

    Amgen (AMGN) Gains But Lags Market: What You Should Know

    Amgen (AMGN) closed the most recent trading day at $196.69, moving +0.31% from the previous trading session.

  • Is Amgen, Inc. (AMGN) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey

    Is Amgen, Inc. (AMGN) A Good Stock To Buy According To Hedge Funds?

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]

  • Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
    PR Newswire

    Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

    THOUSAND OAKS, Calif. and PITTSBURGH, Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King Mellon Foundation, the region's students will become a part of the Amgen Foundation's respected international science education program, making it the tenth program site in the United States and the 20th worldwide.

  • Phillips 66 puts former Walmart CFO on board
    American City Business Journals

    Phillips 66 puts former Walmart CFO on board

    Houston’s largest publicly traded company by revenue, Phillips 66 (NYSE: PSX), has a new independent director — former Walmart Inc. (NYSE: WMT) CFO Charles Holley. Phillips 66, which owns and operates downstream and midstream assets, tapped Holley for the job Oct. 4, and he will hold his seat on the board of directors until the next annual shareholder meeting in 2020, according to a company filing with the U.S. Securities and Exchange Commission.

  • Reuters

    UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report

    AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis.

  • Why Alexion is a Hot Takeover Target in the Biotech Sector
    Zacks

    Why Alexion is a Hot Takeover Target in the Biotech Sector

    Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.

  • Benzinga

    Pfenex Gets FDA Seal of Approval For Amgen's Forteo Biosimilar

    The FDA has approved its NDA for PF708 under the 505(b)(2) regulatory pathway, with Amgen, Inc. (NASDAQ: AMGN)'s Forteo as the reference drug. Amgen's Forteo had global sales of $1.6 billion in 2018.

  • Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?

    Is (AMGN) Outperforming Other Medical Stocks This Year?

  • After 500% Surge, Mirati’s Day of Reckoning Is Approaching
    Bloomberg

    After 500% Surge, Mirati’s Day of Reckoning Is Approaching

    (Bloomberg) -- With no drugs on the market and no earnings to speak of, Mirati Therapeutics Inc. has soared more than 500% since September 2017.That’s when the oncology company’s lead product, sitravatinib, showed early promise in lung cancer. But even with a pivotal study for the treatment already in motion, investors have set their sights elsewhere: a yet-to-be proven experimental therapy known only as MRTX849.While Mirati has only guided to a first look at MRTX849 sometime in the fourth quarter, sell-side analysts expect results to be presented as late-breaking data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, a meeting in Boston that kicks off at the end of the month.MRTX849 targets a mutation on the KRAS gene, which in human tumors can spur cancer’s growth. It occurs in about 13% of non-small cell lung cancers and 3% of colon cancers, as well as handful of other tumors. Doctors have long-called the KRAS gene “undruggable,” an impervious target where treatments couldn’t get a foothold. That changed this summer, when Amgen Inc. revealed early data for its rival molecule. Amgen’s AMG 510 spurred a partial response in a handful of lung cancer patients, though the disease returned after a few months in some of them.That promising signal from Amgen was enough to send Mirati’s stock to a record $109.60 a share on July 3, despite a lack of any clinical data for its KRAS drug. Bulls believe MRTX849 may last longer in the body and therefore be more effective than Amgen’s AMG 510. But investor concerns have crept back into shares of both companies after another look at AMG 510 showed that the highest dose helped shrink colon cancer in only one out of 12 patients.Mirati investors have to ask if the disappointing colon cancer response is specific to AMG 510 or applies to the whole KRAS class, SVB Leerink analyst Andrew Berens said in a phone interview. Berens, who rates Mirati outperform, says dosing is Amgen’s Achilles’ heel, making it hard to get high concentrations of AMG 510 into patients. “If you don’t get enough of the drug into the tissue, you aren’t going to get complete efficacy,” he cautioned. Berens doesn’t cover Amgen; the stock is rated market perform by another Leerink analyst.Wall Street has been bullish to neutral on Mirati with one exception: JPMorgan’s Anupam Rama. He gave the San Diego, California-based company its first ever sell-equivalent rating in August, shortly after Mirati reached a record. Expectations were too high and the downside was underappreciated, Rama warned clients in a note. Even if Mirati shows response rates as high as 60% -- similar to AMG 510 in lung cancer -- that could be viewed as a “downside scenario,” he wrote recently.Rama said some investors may look on Mirati as a buyout target even if its results are merely comparable to Amgen’s data. He argues a takeover is unlikely to happen until its drug has established “some reasonable durability,” and that will take time. Rama expects Mirati’s medicine could ultimately outperform AMG 510 on the length of responses and how long patients live before their disease gets worse. The problem -- and the basis for Rama’s underweight call -- is the evidence isn’t likely to emerge during the first look at Mirati’s drug, and questions over durability won’t be answered in the near future. Mirati’s market valuation was just shy of $3 billion as of Friday’s close.Meanwhile, competition has been heating up. Johnson & Johnson started its own study, as has the closely held German company, Boehringer Ingelheim GmbH. Boehringer will study its KRAS-inhibitor alone as well as in combination with other cancer drugs, an area where Amgen has also expressed interest.Bearish bets against Mirati stand at 15% of the drugmaker’s float, according to S3 Partners data. Options in Mirati set to expire on Oct. 18 show investors expect shares to move about 13% over the next two weeks. The at-the-money straddle set to expire in November is showing an expected price move of 34%. Implied volatility is elevated at about 129% versus a 90-day average of 70.\--With assistance from Gregory Calderone.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Michelle Fay CortezFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering
    Investor's Business Daily

    A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering

    Shares of Coherus Biosciences popped Friday on the possibility a rival biosimilar from Novartis may have been delayed. Coherus knocks off Amgen's branded drug, Neulasta, with a copycat drug.

  • 3 Drug Stocks Poised for Gains After Cancer Conference
    Investopedia

    3 Drug Stocks Poised for Gains After Cancer Conference

    Drug stocks have moved higher after an upbeat European cancer conference. Play three leading names using these tactical trading ideas.

  • Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It?
    Investor's Business Daily

    Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It?

    Shares of Amgen are on an upswing after the company won a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?

  • Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Amgen (AMGN) closed at $192.62, marking a +1.8% move from the previous day.

  • Benzinga

    Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

    Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization.

  • Merck's Pediatric Filings for Dificid Get FDA's Priority Review
    Zacks

    Merck's Pediatric Filings for Dificid Get FDA's Priority Review

    The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.

  • Barrons.com

    Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona

    Companies including Amgen, Merck & Co., and Incyte offered positive news on a range of therapies at a major cancer conference sponsored by the European Society for Medical Oncology.

  • Seeing the Baseline
    GuruFocus.com

    Seeing the Baseline

    As contrarian value investors, we not only believe reversion is an eventuality, but that money can be made when the majority believe it to be dead Continue reading...

  • Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
    Zacks

    Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)

    Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Top Ranked Income Stocks to Buy for October 2nd
    Zacks

    Top Ranked Income Stocks to Buy for October 2nd

    Top Ranked Income Stocks to Buy for October 2nd